文献速递肾癌与肾肿瘤

转移性肾细胞癌一线治疗后的无治疗生存期:国际转移性肾细胞癌数据库联盟分析

Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis.
PubMed 文献 · Eur Urol Oncol · 2024-12-31

该研究基于IMDC多中心数据库,分析2014年2月1日至2023年2月1日期间3758例转移性肾细胞癌患者,比较一线VEGFR单药、ICB+VEGFR联合及双ICB方案的无治疗生存期(TFS)。结果显示,在IMDC中/高危组中,双ICB组36个月TFS长于VEGFR单药组;TFS可作为信息性终点,为临床决策提供生存估计。

要点

  • IMDC中/高危组36个月TFS:VEGFR单药组2.1个月(95%CI 1.4-2.8),ICB+VEGFR组3.7个月(95%CI 1.0-6.4),双ICB组5.3个月(95%CI 3.8-6.8)。
  • IMDC favorable-risk组36个月TFS:VEGFR单药组3.1个月(95%CI 1.5-4.6),ICB+VEGFR组3.7个月(95%CI 0.2-7.2)。
  • TFS可作为信息性终点,为mRCC决策提供生存估计。

核心结论

  • 在IMDC中/高危风险的mRCC患者中,一线双ICB治疗的TFS长于VEGFR单药治疗。
  • TFS可作为信息性终点,为mRCC决策提供生存估计。

研究设计与样本

  • 多中心回顾性分析,数据来自国际转移性肾细胞癌数据库联盟(IMDC)数据库。
  • 纳入2014年2月1日至2023年2月1日期间开始一线系统治疗的mRCC患者3758例。
  • 分组:VEGFR单药组n=2635,ICB+VEGFR联合组n=354,双ICB组n=769。
  • 36个月TFS估计为一线治疗停止时间与后续系统治疗开始时间之间的限制性平均生存时间差值。

主要发现

  • IMDC favorable-risk组36个月TFS:VEGFR单药组3.1个月(95%CI 1.5-4.6),ICB+VEGFR组3.7个月(95%CI 0.2-7.2)。
  • IMDC中/高危组36个月TFS:VEGFR单药组2.1个月(95%CI 1.4-2.8),ICB+VEGFR组3.7个月(95%CI 1.0-6.4),双ICB组5.3个月(95%CI 3.8-6.8)。

临床怎么用

  • 作者认为,TFS可作为信息性终点,并为mRCC决策提供生存估计。

局限性

  • 回顾性设计。
  • 无法量化不良事件所占时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Patients receiving immune checkpoint blockade (ICB) therapy may experience periods of prolonged disease control without a need for systemic therapy. Treatment-free survival (TFS) is an important measure for this period, but no data are available for patients with metastatic renal cell carcinoma (mRCC) starting first-line agents. Our aim was to analyze TFS outcomes for patients with mRCC starting first-line therapy. METHODS: We analyzed data for patients with mRCC starting first-line systemic therapy with VEGFR-targeted monotherapy, an ICB + VEGFR combination, or an ICB doublet from February 1, 2014 to February 1, 2023 from the multicenter International Metastatic RCC Database Consortium (IMDC) database. We estimated 36-mo TFS as the difference in restricted mean survival time between (1) the time to first-line therapy discontinuation and (2) the time to subsequent systemic therapy initiation. KEY FINDINGS AND LIMITATIONS: The study population included 3758 patients receiving either first-line VEGFR monotherapy (n = 2635), an ICB + VEGFR combination (n = 354), or doublet ICB (n = 769) were included. For the IMDC favorable-risk cohort, the 36-mo TFS estimate was 3.1 mo (95% confidence interval [CI] 1.5-4.6) for the VEGFR monotherapy group and 3.7 mo (95% CI 0.2-7.2) for the ICB + VEGFR group. For the IMDC intermediate-/poor-risk cohort, TFS was 2.1 mo (95% CI 1.4-2.8) for the VEGFR monotherapy group, 3.7 mo (95% CI 1.0-6.4) for the ICB + VEGFR group, and 5.3 mo (95% CI 3.8-6.8) for ICB doublet group. Limitations include the retrospective design and an inability to quantify time spent with adverse events. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our study demonstrates that patients with IMDC intermediate or poor risk treated with ICB doublet therapy experienced longer TFS than those treated with VEGFR monotherapy in the first-line setting. These results emphasize the utility of TFS as an informative endpoint and provide survival estimates to inform decision-making in mRCC. PATIENT SUMMARY: For patients with metastatic kidney cancer, we compared the survival time free from a second treatment line for different first-line treatment options. The results show that the time free from second-line treatment was longer when first-line treatment was with a combination of two immunotherapy drugs (ipilimumab and nivolumab) in comparison to other treatment options.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Gupta M, Wells C, Regan MM, et al. Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis. Eur Urol Oncol. 2024. PMID: 39743422. doi:10.1016/j.euo.2024.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。